PMID- 29530843
OWN - NLM
STAT- In-Process
LR  - 20190311
IS  - 1098-6596 (Electronic)
IS  - 0066-4804 (Linking)
VI  - 62
IP  - 5
DP  - 2018 May
TI  - Combination of Tedizolid and Daptomycin against Methicillin-Resistant
      Staphylococcus aureus in an In Vitro Model of Simulated Endocardial Vegetations.
LID - e00101-18 [pii]
LID - 10.1128/AAC.00101-18 [doi]
AB  - Methicillin-resistant Staphylococcus aureus (MRSA) is a major pathogen
      responsible for health care-associated infections, and treatment options are
      limited. Tedizolid (TZD) is a novel oxazolidinone antibiotic with activity
      against MRSA. Previously, daptomycin (DAP) has demonstrated synergy with other
      antibiotics against MRSA. We sought to determine the efficacy of the combination 
      of TZD and DAP against MRSA in an in vitro model of simulated endocardial
      vegetations (SEVs). TZD simulations of 200 mg once daily and DAP simulations of 6
      mg/kg of body weight and 10 mg/kg once daily were tested alone and in the
      combinations TZD plus DAP at 6 mg/kg or DAP at 10 mg/kg against two clinical
      strains of MRSA, 494 and 67. These regimens were tested in SEV models over 8 days
      to determine the antibacterial activity of the regimens and whether synergy or
      antagonism might be present between the agents. Against both strains 494 and 67
      and at both DAP dose regimens, the combination of TZD and DAP was antagonistic at
      192 h. In all cases, DAP alone was statistically superior to DAP plus TZD. When
      the combination was stopped after 96 h, transitioning to DAP at 6 mg/kg or DAP at
      10 mg/kg alone resulted in better antibacterial activity than either of the
      TZD-plus-DAP combinations, further demonstrating antagonistic effects. Against
      MRSA, we demonstrated that TZD and DAP have antagonistic activity that hinders
      their overall antimicrobial efficacy. The exact nature of this antagonistic
      relationship is still undetermined, but its presence warrants further study of
      the potentially harmful grouping of the two antibiotics in clinical use.
CI  - Copyright (c) 2018 American Society for Microbiology.
FAU - Smith, Jordan R
AU  - Smith JR
AD  - Fred Wilson School of Pharmacy, High Point University, High Point, North
      Carolina, USA.
FAU - Yim, Juwon
AU  - Yim J
AD  - Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene
      Applebaum College of Pharmacy and Health Sciences, Wayne State University,
      Detroit, Michigan, USA.
FAU - Rice, Seth
AU  - Rice S
AD  - Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene
      Applebaum College of Pharmacy and Health Sciences, Wayne State University,
      Detroit, Michigan, USA.
FAU - Stamper, Kyle
AU  - Stamper K
AD  - Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene
      Applebaum College of Pharmacy and Health Sciences, Wayne State University,
      Detroit, Michigan, USA.
FAU - Kebriaei, Razie
AU  - Kebriaei R
AD  - Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene
      Applebaum College of Pharmacy and Health Sciences, Wayne State University,
      Detroit, Michigan, USA.
FAU - Rybak, Michael J
AU  - Rybak MJ
AD  - Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene
      Applebaum College of Pharmacy and Health Sciences, Wayne State University,
      Detroit, Michigan, USA m.rybak@wayne.edu.
AD  - School of Medicine, Wayne State University, Detroit, Michigan, USA.
AD  - Detroit Receiving Hospital, Detroit, Michigan, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20180426
PL  - United States
TA  - Antimicrob Agents Chemother
JT  - Antimicrobial agents and chemotherapy
JID - 0315061
PMC - PMC5923122
OTO - NOTNLM
OT  - *daptomycin
OT  - *in vitro
OT  - *lipoglycopeptide
OT  - *tedizolid
EDAT- 2018/03/14 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/14 06:00
PHST- 2018/01/16 00:00 [received]
PHST- 2018/02/28 00:00 [accepted]
PHST- 2018/03/14 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
PHST- 2018/03/14 06:00 [entrez]
AID - AAC.00101-18 [pii]
AID - 10.1128/AAC.00101-18 [doi]
PST - epublish
SO  - Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: AAC.00101-18. doi:
      10.1128/AAC.00101-18. Print 2018 May.